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Abstract
Aldosterone produces a multitude of effects in vivo, including promotion of post-myocardial
infarction adverse cardiac remodeling and heart failure progression. It is produced and secreted
by the adrenocortical zona glomerulosa (AZG) cells after angiotensin II (AngII) activation of
AngII type 1 receptors (AT1Rs). Up until now, the general consensus for AngII signaling to
aldosterone production has been that it proceeds via activation of Gq/11-proteins, to which the
AT1R normally couples. Here, we describe a novel signaling pathway underlying this AT1Rdependent aldosterone production mediated by β−arrestin (βarr) -1, a universal heptahelical
receptor adapter/scaffolding protein. This pathway results in sustained extracellular signalregulated kinase (ERK) activation and subsequent upregulation of StAR, a steroid transport
protein regulating aldosterone biosynthesis in AZG cells. In addition, this βarr1-mediated
pathway appears capable of promoting aldosterone turnover independently of G-protein
activation, since treatment of AZG cells with SII, an AngII analog that induces βarr, but not Gprotein coupling to the AT1R, recapitulates the effects of AngII on aldosterone production and
secretion. In vivo, increased adrenal βarr1 activity, by means of adrenal-targeted adenoviralmediated gene delivery of a βarr1 transgene, resulted in a marked elevation of circulating
aldosterone levels in otherwise normal animals, suggesting that this adrenocortical βarr1mediated signaling pathway is operative, and promotes aldosterone production and secretion in
vivo, as well. Thus, inhibition of adrenal βarr1 activity on AT1Rs might be of therapeutic value
in pathological conditions characterized and aggravated by hyperaldosteronism.
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\body
Aldosterone is one of a number of hormones that can be detrimental to myocardium, and whose
circulating levels are elevated in chronic heart failure (HF). It contributes significantly to HF
progression after myocardial infarction (MI) and to the morbidity and mortality of the disease (13). Aldosterone`s main actions on the post-MI heart include (but are not limited to) cardiac
hypertrophy, fibrosis, and increased inflammation and oxidative stress, all of which result in
adverse cardiac remodeling and progressive loss of cardiac function and performance (2-4).
Aldosterone is a mineralocorticoid produced and secreted by the cells of the zona
glomerulosa of the adrenal cortex in response to either elevated serum potassium levels or to
angiotensin II (AngII) acting through its type 1A receptors (AT1ARs), which are endogenously
expressed in the adrenocortical zona glomerulosa (AZG) cells (5,6). AT1Rs belong to the
superfamily of 7-transmembrane spanning G-protein coupled receptors (GPCRs), and, upon
agonist activation, couple to the Gq/11 family of G-proteins (6). Over the past few years however,
a number of GPCRs, including the AT1R, have been shown to also signal through G proteinindependent pathways. The protein scaffolding actions of β-arrestin-1 and -2 (βarr1 and -2, also
known as arrestins -2 and -3, respectively), originally discovered as terminators of GPCR
signaling following phosphorylation of these receptors by the GPCR kinases (GRKs), play a
central role in mediating G protein-independent signal transduction by these receptors (7,8).
We recently reported that adrenal GRK2, the major co-factor of βarr action toward
receptors, is upregulated in HF leading, through its concerted action with βarr1, to increased
desensitization/down-regulation of α2-adrenoceptors, and this mediates the increased adrenal
catecholamine output seen in HF (9). Since adrenal aldosterone production stimulated by AngII
is increased in HF (1-3), and βarr1 also regulates AT1R signaling (7,8), we hypothesized that
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adrenal βarr1 might mediate the signaling of AT1R to aldosterone production and secretion. In
order to test this in vitro, we used the human AZG cell line H295R, which endogenously
expresses the AT1R, but not the AT2R (the other AngII receptor type). Importantly, these cells
produce and secrete aldosterone in response to AngII stimulation (10,11). To examine whether
adrenal βarr1 influences aldosterone turnover in vivo, we used our previously developed
methodology for adrenal-targeted, adenoviral-mediated gene transfer (9,12) of wild-type fulllength βarr1 in normal rats. We have uncovered a novel signaling pathway mediated by βarr1
that leads to aldosterone production by the AT1R in AZG cells in vitro, which, importantly, is
also operative in vivo, since adrenal βarr1 overexpression was found to be capable of increasing
circulating levels of aldosterone in vivo.
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Results
βarr1-mediated AngII-induced aldosterone production in vitro. Since AngII is known to
promote aldosterone production in AZG cells, we set out to explore a potential role for βarrs in
this effect. In H295R cells, treatment with 10 nM AngII leads to a significant induction of
aldosterone secretion, as expected (Fig. 1A). Western blotting with an antibody against both βarr
isoforms in native extracts from these cells revealed that only βarr1 is expressed endogenously in
significant amounts (Fig. 1B). Consistent with this, human adrenal glands express βarr1 robustly
(SI Fig. 1), and importantly, βarr1 co-localizes with the known adrenocortical protein,
steroidogenic acute regulatory protein (StAR), in human adrenocortical sections (Fig. 1C).
Aldosterone synthesis in AZG cells is initiated by the mitochondrial uptake of
cholesterol, the precursor of all adrenal steroids (10). Mitochondrial cholesterol uptake is the
rate-limiting step of this procedure and is catalyzed by the steroid transport protein StAR, whose
levels are upregulated in response to AngII stimulation (10,13). Consistent with this, we
observed a large StAR upregulation in H295R cells 6 hrs post-AngII stimulation (Fig. 1B).
In order to test whether endogenous βarr1 plays a role in AngII-induced aldosterone
production/secretion, we transfected H295R cells with the V53D dominant negative βarr1
mutant (DN βarr1), which prevents βarr1 from interacting with its various intracellular nonreceptor binding partners (14,15). As shown in Fig. 1D, DN βarr1 overexpression led to marked
inhibition of AngII-induced aldosterone secretion, compared to control empty vector (EV)transfected cells. In addition, the AngII-induced StAR upregulation normally observed in EVtransfected cells was also absent in DN βarr1-transfected cells (Fig. 1E).

Conversely,
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transfection of H295R cells with an adenovirus encoding for wild-type βarr1 (Adβarr1) led to
significantly enhanced AngII-induced aldosterone secretion compared to control AdGFP (Green
Fluorescent Protein)-transfected cells (Fig. 1F), which was also accompanied by a marked
enhancement of AngII-induced StAR upregulation (Fig. 1G). Taken together, these results show
that βarr1 is necessary for AngII-induced StAR upregulation and subsequent aldosterone
production in AZG cells in vitro.
βarr1-mediated AT1R signaling to aldosterone production involves DAG and sustained
ERK activation.
To further dissect the signaling pathway of AngII-induced aldosterone production mediated by
βarr1 in AZG cells, we focused on βarr1-promoted ERK1/2 activation. ERK1/2 play a central
role in StAR upregulation by means of inducing StAR gene transcription in response to AngII
stimulation in AZG cells (13). βarrs have been shown to mediate AT1R signaling to ERKs in
various heterologous cell systems in vitro (7,8). Following AngII stimulation for various times,
we found that βarr1 overexpression does lead to sustained AngII-induced ERK1/2 activation in
H295R cells, lasting at least 6 hrs and contrary to a more transient ERK1/2 activation by AngII
in control AdGFP-transfected cells (Figs. 2A & 2B). Conversely, inhibition of endogenous βarr1
by DN βarr1 completely abrogates AngII-induced ERK1/2 activation in H295R cells compared
to EV-transfected cells (Figs. 2A & 2B). These data indicate that βarr1 promotes a sustained
AngII-induced ERK1/2 activation, which could underlie the observed βarr1-promoted StAR
upregulation and aldosterone production in response to AngII in AZG cells.
Recently, βarr1 was shown to recruit the diacylglycerol (DAG) kinases (DGKs) to
activated M1 muscarinic cholinergic receptors, which also couple to Gq-proteins like the AT1Rs,
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thereby catalyzing the conversion of the Gq-dependent second messenger DAG to phosphatidic
acid (PA) at the cell membrane (16). PA is a potent ERK cascade activator by means of bringing
together Ras and Raf1 kinase at the level of the plasma membrane to interact with each other
(17). Therefore, we hypothesized that this βarr1-mediated mechanism could be at play in AngIIinduced sustained ERK1/2 activation in AZG cells, as well. To test this, we pretreated
transfected H295R cells with the phospholipase C (PLC) inhibitor U73122 (18) to suppress all
DAG production before AngII stimulation. In the presence of PLC inhibition, βarr1
overexpression is unable to induce StAR upregulation or ERK activation in response to AngII
stimulation, which are also absent in control AdGFP-transfected cells, as expected (Figs. 2D &
2C, respectively, and quantitation in Figs. 2F & 2E, respectively). Adding the cell-permeable
DAG analog dioctanoylglycerol (DiC8-DAG) however (19), which circumvents PLC inhibition
and is a DGK substrate, immediately before applying AngII to the PLC inhibitor-treated cells,
rescues the ability of βarr1 to mediate StAR upregulation and ERK activation in response to
AngII, both in βarr1-overexpressing and in control AdGFP-transfected cells (Figs. 2D & 2C,
respectively, and quantitation in Figs. 2F & 2E, respectively). Importantly, in the presence of
PLC inhibition, βarr1 is also incapable of promoting AngII-induced aldosterone production in
H295R cells (Fig. 2G), and this capability is again rescued by the addition of DiC8-DAG (Fig.
2H). Finally, application of the MEK1 inhibitor PD98059 which abolishes ERK1/2 activation led
to a complete abrogation of AngII-induced ERK activation and StAR upregulation (Figs. 2D &
2C, respectively, and quantitation in Figs. 2F & 2E, respectively), as well as of AngII-induced
aldosterone production (Fig. 2G) both in βarr1-overexpressing and in control AdGFP-transfected
cells, thus confirming the vital role of ERK1/2 in mediation of AngII-induced aldosterone
production in AZG cells (13). Taken together, these results indicate that DAG is necessary for
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βarr1-mediated ERK1/2 activation, StAR upregulation and aldosterone production in AZG cells
induced by AngII, probably via βarr1-recruited DGK-catalyzed conversion to PA.
The βarr1-mediated signaling pathway operates independently of G-protein activation.
Next, we examined whether this βarr1-mediated signaling pathway of AngII-dependent
aldosterone production can proceed without the activation of the cognate AT1R G-protein
pathway. To this end, we took advantage of the well characterized AngII analog [Sar1,Ile4,Ile8]AngII (SII), which is a biased AT1R agonist, in that it does not induce the coupling of AT1R to
G-proteins, but instead induces receptor interaction with βarrs and downstream βarr-mediated
signaling (20). As shown in Fig. 3A, SII, at the relatively high concentration of 10µM, is also
able to induce aldosterone secretion from H295R cells, and this is enhanced in cells
overexpressing βarr1 (Fig. 3A). Conversely, transfection with DN βarr1 abolishes SII-induced
aldosterone secretion (Fig. 3A).

Of note, 1 µM SII treatment could stimulate aldosterone

secretion only in the presence of βarr1 overexpression (data not shown), consistent with far less
potency of this compound at stimulating βarrs compared to AngII (21). In addition, 10µM SII
treatment results also in ERK1/2 activation (Fig. 3B) and StAR upregulation (Fig. 3C), which are
again enhanced by βarr1 overexpression and abrogated by DN βarr1 (Figs. 3B & 3C). Taken
together, these results indicate that βarr1 is able to mediate AT1R signaling to aldosterone
production in AZG cells in its own right, i.e. even without concomitant activation of G-proteins
by the AT1R.
βarr1 mediates aldosterone production in vivo. Next, we examined whether adrenal βarr1 can
affect aldosterone production in vivo, as well. Adrenal gland-specific overexpression of βarr1 in
normal rats via infection with Adβarr1 in vivo led to a significant increase in plasma aldosterone
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levels compared to control AdGFP rats (536+50 pg/ml vs. 235+40 pg/ml, respectively, n=5,
p<0.01) (Fig. 4A) at seven days post-in vivo gene delivery. βarr1 was markedly overexpressed in
the adrenals of Adβarr1 rats (Fig. 4B).
Since GRK2 is a co-factor of βarr1 activity towards receptors, we also delivered an adenovirus
carrying GRK2 (AdGRK2) to normal rat adrenal glands.

As shown in Fig. 4A, GRK2

overexpression resulted in a small but significant increase in plasma aldosterone at 7 days postgene delivery compared to control AdGFP-treated rats (322+20 pg/ml, n=5, p<0.05 vs. AdGFP),
indicating that increased activity/expression of GRK2 in the adrenal gland increases aldosterone
production, as well. This is consistent with induced βarr1 acting at the plasma membrane. Fig.
4B shows the overexpression of the respective transgenes in the adrenals of normal rats. Of note,
all transgenes delivered in vivo displayed adrenal-specific overexpression with no ectopic
expression in any other tissue tested (Ref. 12, and data not shown).

In addition, plasma

aldosterone values in saline-treated rats were similar to AdGFP-treated rats (Fig. 4A), indicating
the absence of any non-specific effects of the adenoviral infection on plasma aldosterone values.
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Discussion
Over the past few years, a novel role for βarr1 and -2, molecules initially discovered as
terminators of G protein signaling by GPCRs, has emerged, i.e. that these two proteins, after
uncoupling the activated receptor from its cognate G-protein, actually serve as signal transducers
for the receptor in their own right (7,8). However, this novel role of βarrs has thus far been
demonstrated almost exclusively in heterologous cell systems in vitro.

The present study

delineates a novel signaling pathway mediated by βarr1, which operates in vitro and in vivo, in a
specialized cell type/tissue (ZG cells of the adrenal cortex), and which leads to an important
physiological effect (AngII-induced aldosterone production).

Moreover, this increased

aldosterone production may then precipitate diseases that are characterized and aggravated by
enhanced circulating levels of this hormone, such as post-MI HF progression (3,4).
Additionally, our data strongly suggest that blocking adrenal βarr1 actions on AT1R
might serve as a novel therapeutic strategy for lowering aldosterone levels in pathological
conditions characterized and precipitated by elevated aldosterone levels, one of the most
important of which is post-MI progression to HF. Testing the effects of adrenal βarr1 inhibition
in vivo in post-MI HF in order to validate this important receptor regulatory protein as a novel
therapeutic target in HF will be the focus of our next study.
Suppression of aldosterone production at its various sources, the most important of which
physiologically is the adrenal cortex, is of particular importance, since aldosterone has been
shown to exert some of its actions (its so-called “non-genomic” actions) by binding other
molecular targets than the mineralocorticoid receptor (MR), the molecular target that normally
mediates its cellular actions (2,3). These MR-independent actions are of course unaffected by the
currently available MR antagonist drugs, such as eplerenone and spironolactone, used in the
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treatment of HF. Therefore, curbing aldosterone production at its major source, i.e. the adrenal
cortex, by inhibiting βarr1 actions, could presumably be more effective therapeutically than
inhibiting its actions at its receptor level and we are planning to investigate this in an in vivo
experimental model of HF.
The pathway of βarr1-dependent AT1R signaling to aldosterone production appears to be
initiated by the recruitment of βarr1 to the activated AT1R which scaffolds DGK(s) to the
activated receptor. This, in turn, leads to conversion of DAG to PA, a membrane phospholipid
that can directly activate the ERK cascade. The resulting sustained ERK activation leads to
activation of StAR gene transcription, thereby causing up-regulation of this cholesteroltransporting protein. The StAR-facilitated mitochondrial uptake of cholesterol subsequently
initiates aldosterone synthesis in AZG cells. This signaling pathway is schematically depicted in
Fig. 5. Of note, StAR is the major regulator of the biosynthesis of all adrenal steroids throughout
the adrenal cortex (10), not only of aldosterone, therefore βarr1 is very likely to be involved in
regulation of the synthesis of glucocorticoids and androgens (the other two categories of adrenal
steroids) by the adrenal cortex, as well.
Although AT1R has been shown to result in sustained ERK activation via βarrs, it is the
βarr2 isoform that has actually been shown to mediate this effect, whereas βarr1 has actually
been shown to act in the opposite direction, i.e. rather inhibiting AT1R-induced ERK activation
(22). Recently, it was shown in transfected HEK293 cells that βarr1 only inhibits AT1R signaling
to ERK by classically desensitizing the receptor (i.e. uncoupling it from the G protein), and βarr2
instead promotes the G protein-independent signaling of AT1R to ERKs, but this βarr2-mediated
ERK activation produces no transcriptional effects (23). Our present findings seem to be in
discordance with these studies. However, it should be emphasized here that these studies were
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done in transfected heterologous systems, with overexpressed receptors at supra-physiological
levels, and also with recombinant (not natural) AT1Rs engineered in such a way that they cannot
couple to any G proteins. Given that signaling from a given GPCR to ERKs can vary widely
depending on the relative concentrations of receptor, G-proteins, GRKs, and βarrs, as well as on
the cellular context in general (i.e. cell type and cellular signaling machinery) (8,23), this
apparent discrepancy can be easily explained. Additionally, the H295R cells used in the present
study do not express significant amounts of βarr2 endogenously, so βarr2 is unlikely to be
involved in AngII-induced aldosterone production, at least in this system (see Figure 1B).
Nevertheless, it is entirely plausible that βarr2 might have different or even opposite effects on
the signaling pathway leading from AT1R activation to aldosterone production in other AZG cell
lines or in vivo, and this is going to be the focus of future studies.
βarr-activated ERKs have been shown to be largely retained in the cytosol due to their
association with receptor-arrestin complexes, and thus not to be able to translocate to the nucleus
to induce transcriptional effects (22,23). However, βarr1 localizes in the cytoplasm, as well as in
the nucleus by virtue of possessing a nuclear localization sequence, whereas βarr2 is excluded
from the nucleus due to a nuclear export sequence present in its molecule (24). In fact, βarr1
translocates into the nucleus in response to stimulation of the µ-opioid receptor, a Gi/o-coupled
receptor, wherein it interacts with the p27 and c-Fos promoters and stimulates transcription by
recruiting histone acetyltransferase p300 and enhancing local histone H4 acetylation (25,26). On
the other hand, ERK1/2 not only target nuclear transcription factors, but also numerous other
plasma membrane, cytoplasmic, and cytoskeletal substrates (27), some of which mediate the
reportedly non-transcriptional effects of βarr-activated ERKs, such as chemotactic T- and B-cell
migration (28,29). Some other ERK substrates though, such as the Rsk and Mnk protein kinases,
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can translocate to the nucleus and activate transcription factors, thereby producing the
transcriptional effects of activated ERK1/2 indirectly (27). Indeed, the cardiac-specific
overexpression of a G protein-uncoupled mutant AT1R has been reported, which induces
ERK1/2 activation that promotes a histologically distinct form of cardiac hypertrophy from that
caused by the wild type receptor, with greater cardiomyocyte hypertrophy and less cardiac
fibrosis (30). This suggests that ERK1/2 activated independently of G proteins can produce
transcriptional effects from AT1R activation in vivo, albeit different from the transcriptional
effects of G-protein-activated ERKs. In the same vein, βarr1 was very recently shown in 3T3-L1
adipocytes to mediate ERK activation from the endogenous TNFα receptor (a cytokine receptor)
through Gq/11-proteins, and this βarr1-mediated ERK activation coupled TNFα receptor
activation to lipolysis, phosphatidylinositol 3-kinase activation and inflammatory gene
expression (31). Taken together, all these studies indicate that βarr1-activated ERK1/2 can lead
to transcriptional effects, which is in complete agreement with our present findings, i.e. that
βarr1-activated ERK1/2 increases StAR expression and aldosterone synthesis in AZG cells.
Indeed, βarr1-activated ERK1/2 appears to increase StAR expression in H295R cells
transcriptionally, via suppression of the early intermediate gene DAX-1 (13), a transcriptional
repressor of the StAR gene (data not shown).
The final important finding of the present study is that SII can completely recapitulate the
AngII effects on aldosterone production, albeit at significantly lower concentrations, consistent
with its lower potency at AT1R compared to the physiological full agonist AngII. This finding
has enormous pharmacological and therapeutic ramifications, since it strongly argues for the
existence of at least two different active conformations of the AT1R, one of which would lead
only to βarr1 but not G-protein activation, but which both result in aldosterone production in
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AZG cells. Therefore, complete blockade of both of these conformations would be warranted in
order to achieve the most effective suppression of AngII-dependent aldosterone production. To
our knowledge, the relative efficacy of the currently available AT1R antagonist drugs (the
sartans) at inhibiting these two signaling pathways emanating from AT1R (i.e. the G protein- and
the βarr-mediated) has never been tested and is completely unknown and thus will also be the
focus of our future studies. In fact, there have been several reports of limited efficacy of some
AT1R antagonists at suppressing aldosterone in HF (32-34), despite their more or less equal
capability to inhibit G-protein activation by the AT1R. It would thus be interesting to examine
whether variations in the efficacy of these agents at inhibiting AT1R−βarr coupling could
account for their reduced efficacy at suppressing aldosterone. Based on the results of the present
study however, the most effective AT1R antagonist at inhibiting AngII-dependent aldosterone
production should be an agent that would inhibit both AT1R-G protein and AT1R-βarr1 coupling
equally well.
In conclusion, the present study reports a novel, G protein-independent signaling pathway
mediated by βarr1 in adrenocortical zona glomerulosa cells that underlies aldosterone production
in response to AngII in vitro and in vivo. Activity of this pathway appears to regulate adrenal
aldosterone production, and hence circulating levels of this mineralocorticoid in vivo. Thus,
adrenal βarr1 activity towards the AT1R might represent a novel therapeutic target for reducing
plasma aldosterone levels in pathological conditions where this is desirable, including several
endocrinological disorders characterized by hyperaldosteronism and cardiovascular disease.
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Methods
Materials. [Sar1,Ile4,Ile8]-AngII (SII) was a generous gift from Dr. P. Cordopatis (University of
Patras School of Pharmacy, Patras, Greece). U73122 was from Biomol (Plymouth Meeting, PA,
USA) and DiC8-DAG from Sigma (Sigma-Aldrich, St Louis, MO, USA).
In vivo adrenal gene delivery in normal rats. All animal procedures and experiments were
performed in accordance with the guidelines of the IACUC of Thomas Jefferson University.
Adrenal-specific in vivo gene delivery was done essentially as described (12), via direct delivery
of adenovirus in the adrenal glands.
Construction and purification of adenoviruses. Recombinant adenoviruses that encode GRK2
(AdGRK2) or rat wild type, full length β-arrestin1 (Adβarr1) were constructed as described
previously (9). Briefly, transgenes were cloned into shuttle vector pAdTrack-CMV, which
harbors a CMV-driven green fluorescent protein (GFP), to form the viral constructs by using
standard cloning protocols. As control adenovirus, empty vector which expressed only GFP
(AdGFP) was used. The resultant adenoviruses were purified, as described previously, using two
sequential rounds of CsCl density gradient ultracentrifugation (9).
H295R cell culture and transfection. H295R cells were purchased from American Type
Culture Collection (Manassas, VA, USA) and cultured as previously described (35). Transfection
was performed either with Adβarr1 or AdGFP or with pcDNA3.1 plasmid encoding either for
the V53D dominant negative βarr1 mutant (14) (DN βarr1, a generous gift of Dr. Lefkowitz,
Duke University Medical Center, Durham, NC, USA) or just empty pcDNA3.1 vector (EV).
Plasmid transfections were performed using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA).
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Plasma and in vitro aldosterone secretion measurements. Rat plasma aldosterone levels and
in vitro aldosterone secretion in the culture medium of H295R cells were determined by EIA
(Aldosterone EIA kit, ALPCO Diagnostics, Salem, NH, USA), as described (34).
Western blotting. Western blots to assess protein levels of StAR (sc-25806), GRK2 (sc-562;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-ERK1/2 (#9106), total ERK1/2
(#4696), and total ERK2 (#9108; Cell Signaling Technology, Danvers, MA), βarr1 (A1CT
antibody, Ref. 16, a generous gift of Dr. Lefkowitz, Duke University Medical Center, Durham,
NC, USA), and GAPDH (MAB374; Chemicon, Temecula, CA, USA) were done using protein
extracts from rat adrenal glands or in H295R cell extracts, as described previously (9).
Visualization of western blot signals was performed with Alexa Fluor 680– (Molecular Probes)
or IRDye 800CW–coupled (Rockland Inc.) secondary antibodies on a LI-COR infrared imager
(Odyssey).
Co-immunofluorescence. Immunofluorescence imaging of human adrenal cross-sections was
carried out as described previously (9). Briefly, human adrenal cross-sections were fixed,
permeabilized and labeled with rabbit polyclonal anti-StAR (sc-25806) and goat anti-βarr1 (sc9182; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies, followed by the
corresponding Alexa Fluor 594 anti-goat (red) and Alexa Fluor 568 anti-rabbit (green) secondary
antibodies (Molecular Probes, Eugene, OR, USA). Confocal images were obtained using a ×40
objective on a Leica Microsystems TCS SP laser scanning confocal microscope.
Statistical analyses. Data are generally expressed as mean ± SEM. Unpaired 2-tailed Student’s t
test and one- or two-way ANOVA with Bonferroni test were generally performed for statistical
comparisons, unless otherwise indicated.

For all tests, a p value of <0.05 was generally

considered to be significant.
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Figure Legends
Fig. 1. Involvement of βarr1 in AngII-induced aldosterone production and secretion in H295R
cells. (A) Aldosterone secretion in response to 10 nM AngII treatment (AngII) or vehicle
(Control) for 6 hrs in H295R cells. *, p<0.05, n=4 independent experiments. (B) Top:
Representative immunoblots for endogenous βarrs and StAR in protein extracts from vehicle(Cont.) and AngII-treated (AngII) H295R cells, including blots for GAPDH as loading control. A
lane run with extract from HEK293 cells (HEK), as a positive control for both βarr isoforms, is
also shown. Bottom: Densitometric analysis of StAR protein expression normalized to GAPDH
levels. *, p<0.05, n=4 independent experiments. (C) Co-immunofluorescence in sections of
human adrenal glands using antibodies specific for StAR (green) and βarr1 (red), showing colocalization of the two fluorescent signals (yellow), which indicates endogenous expression of
βarr1 in human adrenocortical cells. Scale bar: 100 µm. (D) Aldosterone secretion in H295R
cells transfected with empty vector (EV) or with a plasmid encoding for the V53D dominant
negative βarr1 (DN βarr1), and stimulated with 10 nM AngII or vehicle for 6 hrs. *, p<0.05, n=5
independent experiments. (E) Western blotting for StAR in these cells at the end of the indicated
treatments. Blots for βarr1 to confirm DN βarr1 overexpression are also shown, along with
GAPDH as loading control. On top: representative blots, on bottom: densitometric quantification
of 5 independent experiments. *, p<0.05, n=5. (F) Aldosterone secretion in H295R cells
transfected with Adβarr1 or AdGFP, and stimulated with 10 nM AngII or vehicle for 6 hrs. *,
p<0.05, n=5 independent experiments. (G) Western blotting for StAR. Representative blots
confirming the overexpression of βarr1, along with GAPDH as loading control, are shown on
top, and the densitometric quantification of 5 independent experiments on bottom. *, p<0.01,
n=5.
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Fig. 2. βarr1-mediated AngII signaling to aldosterone production in H295R cells. (A) Western
blotting for phospho-ERK1/2 and for total ERK2 in extracts from transfected H295R cells after
10 nM AngII stimulation for the indicated times. Representative blots of 3 independent
experiments are shown, including blots for βarr1 to confirm the overexpression of the transfected
proteins. (B) Densitometric quantification of the 3 independent experiments performed in (A). *,
p<0.05, vs. AdGFP, **, p<0.05, vs. DN βarr1. (C,D) Western blotting in control AdGFP- or in
Adβarr1-transfected H295R cells treated with vehicle or 10 nM AngII for 6 hrs following
pretreatment with 10 µM U73122, 10 µM U73122 plus 10 µM DiC8-DAG, or 50 µM PD98059.
Representative blots of 3 independent experiments for each cell line are shown, including blots
for endogenous βarr1 and for total ERK1/2 and GAPDH as loading controls. (E,F) AngIIinduced ERK phosphorylation and StAR upregulation as densitometrically quantitated in the 3
independent experiments performed in (C) and (D), respectively. Values are expressed as % of
the AngII response of cells not pretreated with any agent (No Inhibitor). *, p<0.05, vs. No
Inhibitor, n=3. (G) Aldosterone secretion in Adβarr1- or AdGFP-transfected cells pretreated with
10 µM U73122 or µM PD98059, followed by 10 nM AngII or vehicle stimulation for 6 hrs. No
significant differences at p=0.05, n=3 independent experiments. (H) Aldosterone secretion in
Adβarr1- or AdGFP-transfected cells pretreated with 10 µM U73122 plus 10 µM DiC8-DAG,
followed by 10 nM AngII or vehicle stimulation for 6 hrs. *, p<0.05, vs. –AngII, n=3
independent experiments.

Fig. 3. SII-induced aldosterone production and secretion in H295R cells. (A) Aldosterone
secretion in transfected H295R cells stimulated with 10 µM SII or vehicle for 6 hrs. Data are
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shown as the % induction over vehicle (basal) levels of aldosterone secretion. *, p<0.05, vs.
AdGFP or EV, n=5 independent determinations/treatment. (B) Western blotting for phosphoERK1/2 and for total ERK2 after 10 µM SII or vehicle. Representative blots of 3 independent
experiments are shown on top and the % SII-induced ERK activation (over basal), as derived by
densitometric quantification, is shown on bottom. *, p<0.05, n=3 independent experiments. (C)
Western blotting for StAR after 10 µM SII or vehicle. Representative blots of 3 independent
experiments are shown on top, including blots for βarr1 to confirm the overexpression of the
respective constructs and for GAPDH as loading control, and the % SII-induced StAR induction
(over basal), as derived by densitometric quantification, is shown on bottom. *, p<0.05, n=3
independent experiments.

Fig. 4. In vivo adrenal-targeted βarr1 overexpression and aldosterone production in normal rats.
(A) Plasma aldosterone levels in AdGFP-, AdGRK2-, or Adβarr1-treated, plus in saline-treated
(Saline), normal rats at 7 days post-in vivo gene transfer. *, p<0.05, **, p<0.01, vs. AdGFP or
Saline, n=5 rats/group. (B) Representative western blots in protein extracts from adrenal glands
from these rats, confirming the overexpression of the respective transgenes. GAPDH is also
shown as loading control.
Fig. 5. Schematic representation of the signaling pathway of AngII-induced aldosterone
production mediated by βarr1. See text for details. ZG: Zona Glomerulosa, AngII: Angiotensin
II, AT1R: AngII receptor type I, βarr1: beta-arrestin 1 (arrestin-2), Gq: Gq protein, PLC:
Phospholipase C, PIP2: Phosphatidylinositol 4`,5`-bisphosphate, DAG: Diacylglycerol, IP3:
Inositol 1`,4`,5`- trisphosphate, DGK: Diacylglycerol kinase, PA: Phosphatidic acid, pERK:
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phospho-Extracellular Signal-Regulated Kinase, MEK1: MAPK-ERK Kinase-1, StAR:
Steroidogenic Acute Regulatory protein.
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